ArticleJournal of surgical oncology2025
Safety and Feasibility of Pulsed Electric Field Ablation for Early-Stage Non-Small Cell Lung Cancer Prior to Surgical Resection.
Article in Journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Addition of pulsed electric field ablation to SBRT for lung tumors: effect on health-related quality of life.Lung cancer management · 2026Article
- Bronchoscopic Ablation and Intratumoral Therapies for Lung Cancer: Expanding Local Treatment Beyond Surgical Resection.Cancers · 2026Review
- Production of Large Ellipsoidal Ablations Using Integrated Nanosecond Pulse Irreversible Electroporation Administered via a Single Applicator and Grounding Pad.Journal of vascular and interventional radiology : JVIR · 2026Article
- Pulsed Electric Field Ablation Reprograms Tumor Immunity and Stimulates Germinal Center Formation in Tertiary Lymphoid Structures in Patients with Non-Small Cell Lung Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Safety and Efficacy of Bronchoscopic Pulsed Electric Field Ablation for Lung Cancer and Metastases.JTO clinical and research reports · 2026Article
- The future of tertiary lymphoid structures in cancer immunotherapy as biomarkers and therapeutic targets.Nature cancer · 2026Article
- Safety and pathologic response of neoadjuvant pulsed electric field ablation and systemic therapy in early-stage resectable lung cancer: case series.Journal of thoracic disease · 2026Article
- See and Strike: A Dual-Force Paradigm for Real-Time Lung Cancer Diagnosis and Non-Thermal Ablation.Diagnostics (Basel, Switzerland) · 2026Review
- Article
- The role of pulsed electric field therapy in non-small cell lung cancer: a narrative review of a novel minimally invasive intervention.Journal of thoracic disease · 2026Review
- Dose Is a Critical Factor Affecting Treatment Volumes for Integrated Nanosecond Pulse Irreversible Electroporation (INSPIRE).IEEE transactions on bio-medical engineering · 2026Article
- Research status and trend of lung cancer ablation therapy: a bibliometric analysis from 2002 to 2025.Journal of thoracic disease · 2026Article
- Bronchoscopic ablation for non-small cell lung cancer.Journal of thoracic disease · 2025Review
- Article
- Robotic-assisted and electromagnetic navigation bronchoscopy for multi-focal lung cancers: a narrative review.Translational lung cancer research · 2025Review
- Six-Month Local Control Rates and Immune Responses After Pulsed Electric Field Ablation in Metastatic Cancer.Cancers · 2025Article
- Article
- AIM (Anticipate/Adjust, Image, Manage) to Prevent Bleeding During Robotically-Assisted Bronchoscopic Ablation.Respirology case reports · 2025Article
- Pulsed electric fields: a sharp sword in the battle against cancers.Frontiers in immunology · 2025Review
- Bronchoscopic Pulsed Electric Field for Ablation and Inmunomodulation in Early-stage Non-small Lung Cancer: A Case Report.Open respiratory archives · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
BACKGROUND AND
methodsSurgery remains the standard of care for non-small cell lung cancer (NSCLC) but is applicable to ≤ 30% of patients. Pulsed Electric Fields (PEF) ablation uses short-duration, high-voltage electrical pulses to induce cell death without relying on thermal mechanisms. Safety findings are reported from a two-arm, non-randomized, study evaluating the use of PEF in patients with early-stage NSCLC.
methodsPEF energy was delivered bronchoscopically or percutaneously to 36 patients with suspected or confirmed early-stage NSCLC approximately 20 days before resection; 8 control patients had biopsy only. The primary safety analysis was the device and/or procedure related serious adverse events (AEs) rate from PEF procedure through resection. Immunohistochemical evaluation of resected tissue was also assessed.
resultsPEF was delivered to all patients in the treatment group after biopsy of targeted tumor. No device or procedure-related AE were observed. Histopathological assessment of resected tumors demonstrated a cellular depletion zone characterized by decrease or absence of tumor cellularity and a variable degree of inflammation. Tertiary lymphoid structures were observed within PEF-treated tumors.
conclusionsThese clinical observations and histopathologic tissue alterations, indicate that PEF energy delivery is feasible and safe in NSCLC, with potential signals of immune system activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.